Compare XLO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XLO | EVAX |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 42.7M |
| IPO Year | 2021 | 2021 |
| Metric | XLO | EVAX |
|---|---|---|
| Price | $0.65 | $6.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $12.33 |
| AVG Volume (30 Days) | ★ 528.0K | 100.4K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,804,000.00 | $7,650,000.00 |
| Revenue This Year | $589.60 | $128.77 |
| Revenue Next Year | $38.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 588.40 | 132.17 |
| 52 Week Low | $0.62 | $1.20 |
| 52 Week High | $1.70 | $12.15 |
| Indicator | XLO | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 50.34 |
| Support Level | $0.68 | $6.15 |
| Resistance Level | $0.73 | $6.70 |
| Average True Range (ATR) | 0.04 | 0.51 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 10.24 | 41.88 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.